EPISODE · Jul 21, 2025 · 9 MIN
On a visit through London today, NodThera's CEO Dan Swisher discusses the company's brain-penetrant NLRP3 platform, including an asset that's in phase 2 for weight loss
from BiotechTV - News · host BiotechTV
He discusses the science behind NLRP3, and describes why he thinks NodThera's brain penetration differentiates it from other programs from pharma and other companies. The weight loss program is a oral therapy that doesn't require titration and hasn't shown GI tolerability side effects.
Embed this episode
Ready to play
On a visit through London today, NodThera's CEO Dan Swisher discusses the company's brain-penetrant NLRP3 platform, including an asset that's in phase 2 for weight loss
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.